口腔鳞状细胞癌患者60例血清MMP-9和TIMP-1水平及其临床意义

[目的]探讨基质金属蛋白酶-9（MMP-9）及基质金属蛋白酶组织抑制因子-1（TIMP-1）在口腔鳞状细胞癌（OSCC）中的水平及意义。[方法]用ELISA法检测60例OSCC患者、26例口腔非典型增生患者术前及30名健康对照者血清中MMP-9、TIMP-1水平。[结果]OSCC患者血清MMP-9水平为21.67±4.21ng/ml,显著性高于口腔非典型增生组（15.43±2.35ng/ml）和正常对照组（11.29±4.78ng/ml）（P〈0.05）。三组间TIMP-1水平及MMP-9/TIMP-1值无统计学差异。OSCC患者淋巴结转移组MMP-9水平为24.71±4.08ng/ml,显著高于未转移组的17.68±3.86ng/ml（t=6.77,P〈0.01）;肿瘤直径〉3cm者MMP-9水平高于肿瘤直径≤3cm者（24.13±4.13ng/mlvs18.85±4.31ng/ml,t=4.84,P〈0.01）。[结论]OSCC患者血清MMP-9水平显著升高,检测OSCC患者血清MMP-9水平有助于判断OSCC发生、转移。     

胃癌组织MMP-9基因及蛋白表达与肿瘤临床病理关系研究

目的:研究胃癌患者基质金属蛋白酶-9表达与肿瘤临床病理参数之间相关性。方法:应用酶联免疫吸附(ELISA)方法检测术前外周血清及胃液中MMP-9蛋白水平。结果:胃癌组、对照组血清中金属蛋白酶平均水平分别为406.03±257.18 ng/m l、167.35±54.04 ng/m l,(P<0.01);TNM晚期、淋巴结转移阳性者术前外周血清蛋白含量显著高于TNM早期、淋巴结转移阴性者(P<0.01)。胃癌组术前胃液中MMP-9蛋白平均水平为77.59±191.97ng/m l,对照组胃液中MMP-9蛋白平均水平为0.81±2.39ng/m l,(P<0.01)。肿瘤侵犯至浆膜层、TNM晚期、淋巴结转移阳性者蛋白含量显著高于肿瘤未侵犯至浆膜层、TNM早期、淋巴结转移阴性者(P<0.01)。结论:检测胃癌患者术前胃液中血清中蛋白酶水平能反映肿瘤进展。     

MMP-9在结肠癌中的表达及其临床意义

[目的]探讨MMP-9在结肠癌中的表达及其在结肠癌进展中的临床意义。[方法]采用Real-Time RT—PCR、免疫组化、计算机图像分析方法定量检测200对结肠癌和正常结肠组织中MMP-9mRNA和蛋白水平的表达,分析其与临床病理特征的关系。[结果]在结肠癌组织中的MMP-9mRNA表达水平明显高于正常结肠组织（P=0．001）,MMP-9mRNA表达水平与Dukes分期（r=0．98,P=0．000）,淋巴结转移（r=0．69,P=0．000）及组织学分化程度（r=-0．724,P=0．015）相关。MMP-9蛋白在结肠癌中的免疫组织化学染色强度（1．96±0．10）高于正常结肠组织（1．21±0．20,P=0．003）。MMP-9蛋白表达水平与Dukes分期（r=0．857,P=0．025）及淋巴结转移（r=0．661,P=0．000）相关。[结论]MMP-9在结肠癌中的表达明显升高,在结肠癌的进展中具有重要作用。     

哈萨克族食管癌中MMP-1、MMP-2、MMP-7、TIMP-1和MTA1的表达及其临床病理意义

目的：探讨在新疆哈萨克族食管癌组织中基质金属蛋白酶1、2、7（MMP-1、MMP-2、MMP-7）、基质金属蛋白酶抑制因子1（TIMP-1）和肿瘤转移相关基因1（MTA1）mRNA的表达及其临床意义。方法：采用RT-PCR方法检测75例哈萨克族食管癌标本中MMP-1、MMP-2、MMP-7、TIMP-1和MTA1 mRNA的表达水平,分析其表达与临床病理特征的关系。结果：MMP-1、MMP-2、MMP-7、TIMP-1和MTA1 mRNA在哈萨克族食管癌组织中的表达较正常组织增高,差异均具有统计学意义（P均〈0.05）;且MMP-2、MMP-7、MTA1 mRNA的表达与淋巴结转移有关（P〈0.05）,MMP-1、MMP-7 mRNA的表达与临床分期有关（P〈0.05）;TIMP-1与MMP-1、MMP-7、MTA1的表达呈正相关（r=0.446、0.458、0.333,P均〈0.01）。结论：MMP-1、MMP-2、MMP-7、TIMP-1和MTA1 mRNA表达上调共同参与了哈萨克族食管癌的发生发展过程;MMP-2、MMP-7和MTA1可能是哈萨克族食管癌发生侵袭、转移的主导因素。     

液相芯片分析技术检测乳腺浸润性导管癌患者血清中VEGF和MMP-9的临床意义

目的利用液相芯片分析技术检测血管内皮生长因子(vascular endothelial growth factor,VEGF)、基质金属蛋白酶9(matrix metalloproteinase-9,MMP-9)在乳腺浸润性导管癌(infiltrative ductal carcinoma,IDC)、良性乳腺纤维瘤患者和正常人血清中的表达,探讨其临床诊断价值。方法采用液相芯片分析技术对301例乳腺浸润性导管癌、83例乳腺良性纤维瘤患者及40例正常人血清中VEGF、MMP-9表达水平进行检测,并分析118例IDC患者手术治疗前后VEGF和MMP-9浓度变化。结果血清中VEGF和MMP-9的表达水平:乳腺浸润性导管癌患者分别为(152.76±150.28)pg/ml和(945.09±749.43)ng/ml;乳腺纤维瘤患者为(29.86±16.10)pg/ml和(563.59±183.29)ng/ml;正常人表达量为(52.45±51.39)pg/ml和(267.33±215.60)ng/ml;IDC患者显著高于乳腺纤维瘤患者和正常人(均P<0.05)。乳腺癌患者血清中VEGF、MMP-9表达水平与年龄无关(P>0.05);而与临床分期、原发灶大小及淋巴结转移相关(均P<0.01)。118例IDC患者术后复查血清VEGF、MMP-9表达量分别(135.26±131.20)pg/ml和(680.36±551.77)ng/ml,与术前相比,表达水平明显下降(均P<0.05)。结论利用液相芯片分析技术定量分析血清中VEGF和MMP-9可成为乳腺癌临床诊断和预后评估的有效指标。     

MMP-9和层粘连蛋白受体在乳腺癌组织中的表达及其与转移和预后的关系

背景与目的:以往对乳腺癌细胞外基质与肿瘤转移及患者预后之间关系的研究尚少,且结论不一。本研究探讨乳腺癌组织中基质金属蛋白酶-9(matrixmetalloproteinase-9,MMP-9)及层粘连蛋白受体(lamininreceptor,LM-R)表达与肿瘤转移及患者预后的关系。方法:应用免疫组化方法检测80例乳腺癌组织及10例乳腺增生病组织中MMP-9、LM-R的表达,并用计算机图像分析系统测定表达的吸光度值。采用t检验、方差分析及相关分析方法分析它们与肿瘤转移和患者预后的关系。结果:乳腺癌组织中MMP-9表达显著高于乳腺增生病(t=8.87,P<0.05);在乳腺增生病组织中,LM-R表达于基底膜及部分腺泡和导管的腔缘,在乳腺癌组织中表达于细胞质及胞膜;17例癌间质血管基底膜有LM-R表达的癌组织中,LM-R表达高于血管基底膜无LM-R表达组(t=2.02,P<0.05);LM-R表达与组织学分级有关,分化低者,表达水平高(F=3.27,P<0.05);MMP-9及LM-R表达均与淋巴结转移有关,它们在有3个以上淋巴结转移组的表达低于3个以下及无转移组(tMMP-9=3.42,tLM-R=4.31,P<0.05),原发灶与转移灶的表达呈正相关(rMMP-9=0.654,rLM-R=0.755,P<0.001);MMP-9与孕激素受体负相关性(r=-0.363,P<0.05);MMP-9与LM-R之间呈正相关(r=0.503,P<0.01)。MMP-9及LM-R表达在生存3年以上组低于3年以     

环氧合酶-2和基质金属蛋白酶-9在宫颈癌中的表达及其临床意义

目的研究环氧合酶-2(COX-2)和基质金属蛋白酶-9(MMP-9)在宫颈癌组织中的表达及临床意义。方法采用免疫组化S-P法检测72例宫颈浸润癌(ICC)、16例癌旁正常宫颈上皮(NCE)组织中COX-2和MMP-9的表达,并分析COX-2和MMP-9表达与ICC病理分级、临床分期、间质浸润和淋巴结转移等临床病理特征的关系。结果ICC组织中COX-2和MMP-9的表达显著高于NCE组织,72例ICC中,COX-2阳性表达率为88.9%,MMP-9阳性表达率为94.4%;16例NCE组织中,COX-2阳性表达率为12.5%,MMP-9阳性表达率为43.8%,两组间差异均有统计学意义(P< 0.01)。COX-2表达与ICC的淋巴结转移和间质浸润深度呈正相关(r分别为0.296和0.257)。MMP-9的表达与ICC的临床分期、病理分级呈正相关(r分别为0.329和0.351)。COX-2和MMP-9在宫颈癌组织中的表达强度呈正相关(r=0.297),二者表达的一致率高达86.1%(62/72)。结论COX-2和MMP-9的高表达与宫颈癌的侵袭和发展有关,二者在宫颈癌的细胞增殖、浸润和转移中有协同作用,联合检测二者的表达对于进一步理解宫颈癌的生物学行为和判断预后有一定价值。     

MMP-2、MMP-9在胃癌组织中的表达及其临床意义

目的探讨基质金属蛋白酶（MMP）中,MMP-2、MMP-9在胃癌组织中的表达及其临床意义。方法采用免疫组织化学SP法检测96例胃癌组织及癌旁正常组织中MMP-2、MMP-9的表达。结果胃癌组织中MMP-2、MMP-9阳性表达率分别为72．9％（70／96）及66．7％（64／96）,均明显高于癌旁正常组织（30．2％和31．3％）（P值均〈0．001）;两者的表达均与肿瘤发生部位、浸润深度、临床分期及淋巴结转移呈明显的正相关（P值均〈0．05）,而与患者年龄、性别、肿瘤大小和分化程度无显著相关性（P值均〉0．05）。结论MMP-2、MMP-9高表达与胃癌的临床病理特点和转移、预后密切相关,可作为判定胃癌生物学行为和预后的重要指标。     

Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa.

Proteolytic enzymes, such as type IV collagenases (MMP-2 gelatinase A, 72-kD type IV collagenase and MMP-9 gelatinase B, 92-kD type IV collagenase) play an important role in tumor invasion and metastasis. In the present study the levels of MMP-2 antigenic concentration and immunohistochemical staining were compared in paired colorectal tumor (n = 64) and background colon tissue of the same patients with clinical and pathological staging. The antigenic concentrations were found to be statistically significantly higher in cancer tissue (mean 11.29 ng/mg protein) than in corresponding normal mucosa (10.23 ng/mg protein) (p = 0.008). There was also a positive correlation between MMP-2 antigenic concentration and clinicopathologic parameters such as grade (p < 0.001) and Dukes' stage (p = 0.001), but not with lymph node involvement. Immunohistological localization of MMP-2 was observed in tumor as well as in stromal cells. Staining intensity increased from adenoma to adenocarcinoma. The degree of staining was associated with grade (p < 0.001), Dukes' stage (p < 0.001) and lymph node involvement (p < 0.001).     

Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma

BACKGROUND AND OBJECTIVES: Oral cancer accounts for one third of all malignancies in India where habit of tobacco consumption is the major etiologic factor, which causes field cancerization in oral mucosa. Multiple molecular events in oral mucosa due to field cancerization may be the cause of local and regional lymph node involvement in oral cancer resulting into low overall survival, high recurrence rate, and poor prognosis. Several matrix metalloproteinases (MMPs) have been shown to play an important role in the invasion and metastasis of oral squamous cell carcinoma (SCC). MMP-2 and MMP-9 are capable of degrading type-IV collagen, which is a major component of basement membrane. Therefore, we studied MMP-2 and MMP-9 activation by gelatin zymography, which is cost effective alternate to ELISA method, in patients with oral SCCs to predict their role in metastatic potentials. MATERIALS AND METHODS: Thirty-nine patients of oral SCCs were classified as non-metastatic (n = 28), and metastatic (n = 11) according to regional lymph node involvement. Malignant and adjacent normal tissues of the patients were collected at the time of surgery. Gelatin zymography was carried out using 7.5% polyacrylamide gel under non-denaturing and non-reducing conditions. Zymograms were analyzed densitometrically. Latent and active forms of MMP-2 and MMP-9 were expressed as ng/50 microg of protein. RESULTS: Latent and active forms of MMP-2 and MMP-9 were significantly elevated in malignant tissues as compared to their adjacent normal tissues (P < 0.05). Total MMP-2 and MMP-9 activities were also significantly elevated in malignant tissues as compared to adjacent normal tissues (P = 0.005 and P = 0.028, respectively). Activation ratio of MMP-2 and MMP-9 were significantly elevated in malignant tissues as compared to adjacent normal tissues. Activation of MMP-2 was prominent (11%) than MMP-9 (5%) in malignant tissues. Activation ratio of MMP-2 was significantly elevated in patients with lymph node metastasis than patients without lymph node metastasis (P = 0.005). Receiver's operating characteristic (ROC) curve analysis revealed that activation ratio of MMP-2 discriminate better than and activation ratio of MMP-9 between patients with and without lymph node metastasis. Activation ratio of MMP-2 could predict risk of lymph node metastasis development in patients without lymph node involvement. CONCLUSION: The study concluded that activation of MMP-2 and MMP-9 was significantly higher in malignant tissues as compared to adjacent normal tissues. Further, activation ratio of MMP-2 was significantly elevated in patients with lymph node metastasis as compared to patients without lymph node metastasis, which could predict risk of lymph node metastasis development in node negative patients.     

非小细胞肺癌MMP-2、MMP-9、TIMP-1表达及与预后关系研究

目的　研究非小细胞肺癌中MMP 2、MMP 9、TIMP 1蛋白和mRNA的表达 ,探讨其与淋巴结转移及预后的关系。方法　应用免疫组织化学和原位杂交方法检测非小细胞肺癌患者石蜡包埋肺癌组织中MMP 2、MMP 9、TIMP 1蛋白和mRNA表达。结果　MMP 2、MMP 9、TIMP 1的表达在不同年龄、性别、组织学类型及分化程度间无显著性差异 ,在淋巴结转移与否组间有显著性差异 (P值均 <0 .0 1)。患者术后生存期与淋巴结转移与否、MMP 2及MMP 9的表达强度显著相关 (P值分别为 0 .0 13 0、0 .0 175及 0 .0 0 10 )。MMP 2、MMP 9、TIMP 1mRNA与蛋白表达具有一致性 (P <0 .0 1,P <0 .0 0 5 ,P <0 .0 2 5 )。结论　MMP 2、MMP 9是影响预后的独立指标 ;TIMP 1是影响预后的有意义的指标。     

乳腺癌组织中 VEGF-D、MMP-2及 MMP-9的表达及其临床意义

目的：探讨乳腺癌组织中基质金属蛋白酶-2（MMP-2）、基质金属蛋白酶-9（MMP-9）和血管内皮生长因子D（ VEGF-D）表达的临床意义。方法采用免疫组化法,对60例乳腺癌组织及60例正常组织中 MMP-2、MMP-9及VEGF-D表达情况进行检测。结果60例乳腺癌组织中,MMP-2、MMP-9阳性表达率分别为61．67％、56．67％,VEGF-D阳性表达率为61．67％。 MMP-2、MMP-9及VEGF-D阳性表达率Ⅲ～Ⅳ期者显著高于Ⅰ～Ⅱ期者;低分化者显著高于高、中分化者;有淋巴结转移者显著高于无淋巴结转移者;且MMP-2与VEGF-D表达,MMP-9与VEGF-D表达均呈正相关性。结论低分化、Ⅲ～Ⅳ期乳腺癌患者高表达MMP-2、MMP-9与VEGF-D,MMPs与VEGF-D表达呈正相关性,可通过阻断VEGF-D及MMPs活性控制、治疗乳腺癌。     

非小细胞肺癌患者术后血清VEGF、MMP-9动态变化的研究

背景与目的血管内皮生长因子(vascular endothelial growth factor,VEGF)及基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)在肿瘤的血管生成中起重要作用。研究发现肺癌患者血清VEGF及MMP-9水平升高。本研究旨在监测非小细胞肺癌(non-small cell lung cancer,NSCLC)患者原发肿瘤切除前后的血清VEGF及MMP-9的水平,了解其动态变化规律。方法应用酶联免疫吸附试验(enzyme linked immunosorbent assay,ELISA)检测法,分别监测57例NSCLC及18例肺良性病患者术前、术后第1、7、14天血清VEGF及MMP-9的浓度,30例健康志愿者确定血清VEGF及MMP-9正常水平。结果NSCLC患者术前血清VEGF浓度(685.50pg/mL)显著高于肺良性疾病患者术前(160.90pg/mL)及健康人血清水平(94.40pg/mL)(P<0.01);手术切除肿瘤后,NSCLC患者术后第1、7、14天血清VEGF水平持续升高(1055.60pg/mL、1533.90pg/mL、1882.10pg/mL)(P<0.01)。NSCLC患者术前血清MMP-9浓度(84.48ng/mL),显著高于肺良性疾病患者术前(58.98ng/mL)及健康人血清水平(42.94ng/mL)(P=0.000);手术切除肿瘤后,术后第1天NSCLC患者的血清MMP-9水平显著升高(282.99ng/mL),术后第7、14天逐渐降低(221.14ng/mL、194.78ng/mL)(P<0.01)。结论NSCLC患者血清VEGF及MMP-9水平显著高于肺良性病患者及健康人,原发肿瘤切除后血清VEGF、MMP-9水平显著升高。     

赖氨酰氧化酶和基质金属蛋白酶2在胃癌组织中的表达及其与胃癌转移的关系

目的 探讨赖氨酰氧化酶(LOX)和基质金属蛋白酶2(MMP-2)在胃癌组织中的表达及其与胃癌转移的关系.方法 收集手术切除新鲜胃癌及相应的癌旁胃组织,用逆转录聚合酶链反应(RT-PCR)方法检测LOX mRNA和MMP-2 mRNA表达,Western blot方法检测LOX蛋白和MMP-2蛋白表达.结果 LOX mRNA在胃癌组织和癌旁胃组织中的相对表达量分别为0.5328±0.1367和0.2436±0.1372(P<0.01),MMP-2 mRNA在胃癌组织和癌旁胃组织中的相对表达量分别为0.7980±0.1571和0.3231±0.1672(P<0.05);LOX mRNA在有淋巴结转移和无淋巴结转移的胃癌组织中的相对表达量分别为0.6336±0.1547和0.4914±0.1408,MMP-2 mRNA在有淋巴结转移和无淋巴结转移的胃癌组织中的相对表达量分别为0.8762±0.1381和0.6362±0.1936,差异均有统计学意义(均P<0.05).LOX蛋白在胃癌组织和癌旁胃组织中的相对表达量分别为0.5237±0.1426和0.2972±0.1480(P<0.05),在有淋巴结转移和无淋巴结转移的胃癌组织中相对表达量分别为0.6880±0.1263和0.4944±0.1217(P<0.05);MMP-2蛋白在胃癌组织和癌旁胃组织中的相对表达量分别为0.7365±0.1607和0.3321±0.1480(P<0.05),在有淋巴结转移和无淋巴结转移的胃癌组织中相对表达量分别为0.8097±0.1632和0.5132土0.1366(P<0.05).胃癌组织中,LOX mRNA与MMP-2 mRNA、LOX蛋白与MMP-2蛋白相对表达量呈正相关(r=0.873,P<0.001;r=0.881,P<0.001);在伴有淋巴结转移的胃癌组织中,LOX mRNA与MMP-2 mRNA、LOX蛋白与MMP-2蛋白相对表达量也呈正相关(r=0.923,P<0.001;r=0.972,P<0.001).结论 LOX和MMP-2在胃癌组织中的表达明显高于相应的癌旁胃组织;在伴有淋巴结转移的胃癌组织中,LOX和MMP-2表达高于无淋巴结转移的胃癌组织,且LOX和MMP-2表达呈正相关,提示LOX和MMP-2对胃癌的发生和转移有促进作用,且两者可能有协同作用.

Abstract：

Objective To compare the expressions of lysyl oxidase (LOX) and matrix metalloproteinases-2 (MMP-2) in gastric cancer and pericancerous tissues, in gastric cancers.with and without lymph node metastasis, and to analyze the effects of LOX and MMP-2 on tumor invasion and metastasis.Methods Gastric cancer and pericancerous tissues were collected from 46 patients who underwent surgery.Levels of LOX and MMP-2 mRNA were detected by RT-PCR.Protein abundance of LOX and MMP-2 was examined using Western blot.Results Expressions of LOX and MMP-2 mRNA, and protein in 46 gastric cancers were significantly higher than that in 46 pericancerous tissues.In gastric cancer with lymph node metastasis, the levels of LOX and MMP-2 mRNA and protein were higher than those in gastric cancers without lymph node metastasis ( P < 0.05 ).In the groups of gastric cancer with lymph node metastasis, expression of LOX was positively correlated with MMP-2 protein expression ( P < 0.01 ).Conclusions Expressions of LOX and MMP-2 in gastric cancer tissues are significantly higher than that in pericancerous tissues.The expressions of LOX and MMP-2 in gastric cancer with lymph node metastasis are higher than that in gastric cancer without lymph node metastasis.Expressions of LOX and MMP-2 are positively correlated.The results suggest that LOX and MMP-2 may promote the growth and metastasis of gastric cancer.     

胃癌组织MMP-9基因及蛋白表达与肿瘤临床病理关系研究

目的：研究胃癌患者基质金属蛋白酶-9表达与肿瘤临床病理参数之间相关性。方法：应用酶联免疫吸附（ELISA）方法检测术前外周血清及胃液中MMP-9蛋白水平。结果：胃癌组、对照组血清中金属蛋白酶平均水平分别为406．03±257．18ng／ml、167．35±54．04ng／ml,（P〈0．01）;TNM晚期、淋巴结转移阳性者术前外周血清蛋白含量显著高于TNM早期、淋巴结转移阴性者（P〈0．01）。胃癌组术前胃液中MMP-9蛋白平均水平为77．59±191．97ng／ml,对照组胃液中MMP-9蛋白平均水平为0．81±2．39ng／ml,（P〈0．01）。肿瘤侵犯至浆膜层、TNM晚期、淋巴结转移阳性者蛋白含量显著高于肿瘤未侵犯至浆膜层、TNM早期、淋巴结转移阴性者（P〈0．01）。结论：检测胃癌患者术前胃液中血清中蛋白酶水平能反映肿瘤进展。     

基质金属蛋白酶及其抑制剂在乳腺癌中的表达及其临床意义

背景与目的:基质金属蛋白酶(matrixmetalloproteinase,MMP)与基质金属蛋白酶组织抑制剂(tissueinhibitorofmatrixmetalloproteinase,TIMP)的表达失平衡在肿瘤侵袭、转移过程中起重要作用,但与乳腺癌预后关系的报道少见。本研究探讨MMP-2、MMP-9和TIMP-1、TIMP-2的表达与乳腺癌侵袭、转移和预后的关系。方法:原位杂交、免疫组化检测66例有临床和随访资料的乳腺癌患者的MMP-2mRNA、TIMP-2mRNA和MMP-2、MMP-9、TIMP-1、TIMP-2蛋白表达。统计学分析采用χ2检验、Kaplan-Meier和Cox多因素回归分析。结果MMP-2mRNA、TIMP-2mRNA和MMP-2、MMP-9、TIMP-1TIMP-2蛋白的阳性表达率分别为66.7%(44/66)、65.2%(43/66)和71.2%(47/66)、68.2%(45/66)、40.9%(2766)、69.7%(46/66),其中MMP-2蛋白与MMP-2mRNAMMP-9蛋白及TIMP-2mRNA与TIMP-2蛋白的表达存在显著性正相关(P<0.01);TIMP-1与MMP-9蛋白表达呈负相关(P<0.01)。有淋巴结转移的乳腺癌中MMP-2、MMP-9蛋白表达显著高于无转移者,但TIMP-2mRNA、TIMP-1蛋白表达显著低于无转移者(P<0.05)。乳腺癌中MMP-2mRNA和MMP-9蛋白表达与肿块大小、生存状况有显著性相关(P0.05),此外,MMP-9蛋白表达与临床分期存在正相关性(P<0.01)。绝经和ER表达阴性患者的MMP-2mRNA表达水平增高(P<0.     

开胸手术对非小细胞肺癌患者血清VEGF、MMP-9水平变化的影响分析

目的 分析开胸手术对非小细胞肺癌(non-small cell lung cancer)患者血清VEGF、MMP-9水平变化的影响.方法 将非小细胞肺癌患者79例作为观察组;良性肺部疾病患者56例和健康志愿者25例作为对照组.观察组患者和良性肺部疾病患者均进行了开胸肺切除手术,然后按照病理类型和TNM分期对观察组患者治疗前的VEGF、MMP-9水平进行检测统计,并与健康对照组比较分析,并对治疗前后观察组和良性对照组患者的VEGF、MMP-9水平进行统计分析.结果 按照患者病理类型检测VEGF水平为:腺癌(332.3±82.3)pg/ml,鳞癌(364.5±81.8)pg/ml,其他病理类型(375.8±88.6)pg/ml;所有患者的MMP-9水平分别为腺癌(199.4±82.2)ng/ml,鳞癌(183.2±102.6)ng/ml,其他病理类型(185.1±112.9)ng/ml,所有肺癌患者的VEGF水平和MMP-9水平均显著高于健康对照组(P<0.05).Ⅰ期患者的VEGF水平和MMP-9水平分别为(245.4±54.3)pg/ml和(141.2±58.2)ng/ml,明显低于其他分期患者VEGF水平和MMP-9水平(P<0.05).观察组患者治疗前后VEGF水平和MMP-9水平均显著高于良性对照组患者(P<0.05).结论开胸手术治疗非小细胞肺癌患者,术后患者的VEGF水平和MMP-9水平明显升高,但没有明显的相关性.患者术前VEGF水平和MMP-9水平也明显高于良性肺部疾病患者,且与患者的分化程度相关.     

CD151和MMP-7在结直肠癌中的表达及其临床意义

  目的  探讨人类白细胞分化抗原151（CD151）和基质金属蛋白酶-7（MMP-7）在结直肠癌中的蛋白表达,及其与结直肠癌发生、发展、转移的关系。  方法  采用免疫组织化学染色法检测结直肠癌组织中CD151和MMP-7的蛋白表达,阐明二者与患者临床病理特征之间的关系。  结果  CD151和MMP-7在大肠正常组织中表达的阳性率分别为5%（1/20）和15%（3/20）,在结直肠癌组织中表达的阳性率分别为78%（39/50）和72%（36/50）,CD151和MMP-7在大肠正常组织和结直肠癌组织中的表达差异有统计学意义（χ2=31.086,P<0.05;χ2=18.811,P<0.05）。两种蛋白的阳性表达率与结直肠癌患者的年龄、性别、部位无关联（P>0.05）,但与淋巴结转移、浸润深度、远隔器官转移、肿瘤分化程度、Dukes分期有密切关系（P<0.05）。结直肠癌中CD151和MMP-7两种蛋白的表达强度具有相关性（r_s=0.314,P=0.026）。  结论  CD151和MMP-7在结直肠癌组织中异常高表达并与其发生、发展及浸润转移有密切关系,联合检测可作为判断结直肠癌生物学行为的重要指标。      

Serum levels of matrix metalloproteinase 2 in patients with breast cancer

Matrix metalloproteinases (MMPs) have been reported to be associated with invasive and metastatic behaviors of human malignant tumors. However, there is still limited knowledge about the role of matrix metalloproteinases-2 (MMP-2) in breast cancer. This study was designed with the aim to elucidate the possible relationship between the preoperative circulating MMP-2 and breast cancer. Fifty-seven consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70 degrees C until assayed. The control group consisted of 12 patients with benign breast tumor (six with fibrocystic disease and six with fibroadenoma). Serum concentrations of MMP-2 were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor stage, age, estrogen receptor, lymph node status, and TNM staging were reviewed and recorded. The mean value of serum MMP-2 in patients with invasive breast cancer was 694.3+/-140.5 ng/ml and those of control group were 593.3+/-134.0 ng/ml and the difference was significant (P=0.026). Furthermore, there were significantly higher serum levels of MMP-2 in the patients with more advanced primary tumor staging (P=0.005), in the patients with more advanced lymph node status(P=0.011) and in the patients with more advanced TNM staging (P<0.001). In multivariate analysis, TNM staging (P<0.001) appeared as independent factor regarding the significant higher serum levels of MMP-2. Patients with more advanced TNM staging were shown to have higher serum MMP-2 levels. Thus preoperative serum MMP-2 levels might reflect the severity of invasive breast cancer and deserve further evaluation.